63586-82-3Relevant articles and documents
Design, synthesis, and in vitro evaluation of potential west nile virus protease inhibitors based on the 1-oxo-1,2,3,4-tetrahydroisoquinoline and 1-oxo-1,2-dihydroisoquinoline scaffolds
Dou, Dengfeng,Viwanathan, Prasanth,Li, Yi,He, Guijia,Alliston, Kevin R.,Lushington, Gerald H.,Brown-Clay, Joshua D.,Padmanabhan,Groutas, William C.
experimental part, p. 836 - 843 (2011/01/13)
The 1-oxo-1, 2, 3, 4-tetrahydroisoquinoline and 1-Oxo-1, 2-dihydroisoquinoline scaffolds were utilized in the design and solution phase synthesis of focused libraries of compounds for screening against West Nile Virus (WNV) protease. Exploratory studies have led to the identification of a WNV protease inhibitor (a 1-oxo-1, 2-dihydroisoquinoline-based derivative, 12j) which could potentially serve as a launching pad for a hit-to-lead optimization campaign. The identified hit was devoid of any inhibitory activity toward a panel of mammalian serine proteases.
BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS
-
, (2008/06/13)
The present invention is directed to novel benzothiazo and related heterocyclic group-containing inhibitors of cysteine or serine proteases. Methods for using the same are also described.
Ibotenic acid analogues. Synthesis and biological and in vitro activity of conformationally restricted agonists at central excitatory amino acid receptors
Krogsgaard-Larsen,Nielsen,Curtis
, p. 585 - 591 (2007/10/02)
A number of analogues of ibotenic acid [(RS)-3-hydroxy-5-isoxazoleglycine] were synthesized; they were tested as excitants on neurons in the cat spinal cord, by using microelectrophoretic techniques, and as inhibitors of the binding of kainic acid (KA) in vitro, by using synaptic membranes prepared from rat brains. The excitatory effects of the 3-isoxazolol amino acids (RS)-3-hydroxy-4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridine-7-carboxylic acid (4, 7-HPCA), (RS)-α-amino-3-hydroxy-5,6-dihydro-4H-cyclohept[1,2-d]isoxazole-8-propion ic acid (8, 8-AHCP), (RS)-α-amino-3-hydroxy-7,8-dihydro-6H-cyclohept[1,2-d]isoxazole-4-propion ic acid (12, 4-AHCP), and (RS)-α-(methylamino)-3-hydroxy-5-methyl-4-isoxazolepropionic acid (N-Me-AMPA) were shown to be sensitive to (S)-glutamic acid diethyl ester (GDEE), an antagonist at quisqualic acid (QUIS) receptors, and insensitive to (RS)-2-amino-5-phosphonovaleric acid (2APV), an antagonist at N-methyl-(R)-aspartic acid (NMDA) receptors. The compounds 4 and 12 proved to be particularly potent agonists at the former class of receptor, assumed to represent physiological glutamic acid receptors. The amino acids (RS)-β-(2-carboxyphenyl)alanine (19), an analogue of 12, and (RS)-2-(3-carboxyphenyl)glycine were weak GDEE-sensitive excitants with potencies comparable with that of 8. All of the compounds were tested as inhibitors of KA binding. With the exception of 12 and 19, which showed very low affinity for the KA binding sites, the compounds studied were inactive in this in vitro test system.